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Miltefosine is the only oral treatment for visceral leishmaniasis.
Gastrointestinal discomfort and elevation of serum creatinine and
transaminases are its known side-effects.1 Hemoptysis and
dyspnea have been described in phase IV trials,2,3 but an
association between miltefosine and the development of lung
toxicity has not been demonstrated. To the best of our knowledge,
this is the ﬁrst description of a causal relationship between
miltefosine and pneumonitis.
A 69-year-old man previously diagnosed with chronic lympho-
cytic leukemia, chronic kidney disease (creatinine clearance of
30 ml/min), and chronic obstructive pulmonary disease (COPD)
was treated for isolated laryngeal leishmaniasis in 2008 and 2010
with liposomal amphotericin B. In 2012 a second relapse was
diagnosed. Miltefosine 150 mg daily was prescribed in accordance
with the available guidelines for its use in patients with renal
dysfunction.4 A week later the patient complained of malaise.
Miltefosine was discontinued and the patient improved. Miltefo-
sine was resumed at a lower dose (50 mg daily). Eight days later
the patient attended the emergency department (ED) complaining
of cough and dyspnea. The chest X-ray was normal and he was
diagnosed with an exacerbation of COPD. Levoﬂoxacin 250 mg
daily for 7 days was prescribed. Nevertheless, his respiratoryFigure 1. Chest X-ray showing bilateral interstitial inﬁltrates at patient admission (A). 
revealed an almost complete clearing of the lung inﬁltrates (B).
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http://dx.doi.org/10.1016/j.ijid.2012.12.019symptoms continued to worsen and he returned to the ED 16 days
later, due to severe dyspnea, cough, and hemoptysis. A chest X-ray
disclosed bilateral interstitial lung inﬁltrates (Figure 1A). Mer-
openem, levoﬂoxacin, and trimethoprim–sulfamethoxazole were
prescribed and miltefosine was discontinued. A bronchoscopy
revealed blood clots in the three right lobar bronchi. The larynx
was normal. Sputum, bronchoalveolar aspirate, and bronchoal-
veolar lavage (BAL) ﬂuid cultures were negative for bacteria
(including mycobacteria), fungi, and viruses, as was modiﬁed
toluidine blue O staining for Pneumocystis jiroveci. Galactomannan
antigen in BAL ﬂuid was negative. A cytologic examination of BAL
revealed few lymphocytes and no malignant cells. The patient’s
general condition improved and a new chest X-ray performed 5
days later revealed an almost complete clearing of the inﬁltrates
(Figure 1B). Three months after discharge the patient continued to
be asymptomatic.
The worsening of our patient’s respiratory symptoms under
treatment with miltefosine, followed by the rapid clinical and
radiological improvement after its discontinuation, establishes a
relationship between both events. There was no evidence of
congestive heart failure, infection, or malignancy as alternative
causes of the lung inﬁltrates. Although previously prescribed with
favorable outcomes in patients with renal dysfunction,5 we
consider that this condition might have been a contributing factor
to this adverse event.The follow-up X-ray, performed 5 days after stopping treatment with miltefosine,
ses. Published by Elsevier Ltd. All rights reserved.
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